Aptevo Therapeutics Business Summary

Aptevo Therapeutics Inc. (APVO) is a clinical-stage biotechnology company specializing in the discovery and development of novel immuno-oncology therapeutics. The company generates revenue primarily through strategic research collaborations, licensing agreements for its proprietary ADAPTIR and ADAPTIR-FLEX protein engineering platforms, and milestone-based payments from co-development partners. Its primary business segments are focused on hematology and solid tumor oncology, with a pipeline led by mipletamig (APVO436), a bispecific antibody for acute myeloid leukemia, and ALG.APV-527, a conditional 4-1BB agonist developed in partnership with Alligator Bioscience. Aptevo competes directly with other immunotherapy-focused firms such as Allogene Therapeutics, CytomX Therapeutics, Senti Bio, and MacroGenics, positioning itself as a niche, small-cap innovator leveraging multispecific antibody scaffolds to improve T-cell engagement and reduce off-target toxicity. The company is currently undergoing a strategic leadership transition effective April 1, 2026, with Marvin White—the President and CEO since Aptevo’s 2016 spin-off from Emergent BioSolutions—retiring to become Executive Chair. Jeff Lamothe, the current COO and former CFO with a pedigree including executive roles at Cangene Corporation and Emergent BioSolutions, will succeed White as President and CEO. The executive team is further bolstered by Chief Medical Officer Dirk Huebner, M.D., a veteran of Mersana and Takeda, and SVP/CFO Daphne Taylor, formerly of BioLife Solutions. Notable governance is provided by Lead Independent Director John E. Niederhuber, M.D., a former Director of the National Cancer Institute. The company maintains a financial runway into 2029 supported by a $60 million equity line of credit from Yorkville Advisors Global.